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Case presentation
A 25-year-old white woman was transferred to the John Radcliffe
Hospital, Oxford, at 23 weeks in her first pregnancy because of a blood
pressure of 200/130 mm Hg and intermittent proteinuria. At the age of
17 years, she developed left hemiparesis and a mild concussion after a
fall. A right-sided carotid arteriogram was normal. Her blood pressure
was 120—160/70—96 mm Hg. The neurologic abnormalities persisted.
After a spontaneous "blackout," more investigations, including an air
encephalogram, also were normal. Because marked systolic hyperten-
sion (220/70 mm Hg) with tachycardia was detected when she was 19
years old, she was treated with propranolol. Investigations included
two CT body scans, intravenous pyelography, urinary VMA excretion,
and thyroid function tests, all of which were normal. At the age of 24
years she had right-sided pyelonephritis. The blood pressure was then
220-260/110-180 mm Hg; methyldopa, propranolol, and bendrofluazide
were prescribed. At the age of 25 she again lost consciousness sponta-
neously.
Shortly afterwards she conceived while taking propranolol and
bendrofluazide. At 8 weeks into gestation, her blood pressure was
160/100 mm Hg, settling to 140/90 at 15 weeks. At that time she had no
proteinuria. By the time of her transfer (at 23 weeks), methyldopa,
debrisoquine, and chlorpromazine had been added to the regimen to
control the increasing blood pressure. Physical examination was normal
apart from wasting and reduced function in the left arm. The kidneys
were not palpable and there were no renal artery bruits. Peripheral
pulses were present and synchronous. The retinal arterioles were not
narrowed and no hemorrhages or exudates were present. Fetal size and
heart rate pattern also were normal. The plasma creatinine was 0.5
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mg/dl; uric acid, 4.1 mg/dl; and 24-hour urinary protein excretion, 0.84
g. Platelet count was 293,000/mm3; the ratio of Factor Vill-related
antigen to clotting activity was 1.27. Liver function tests were normal.
Her treatment was changed to methyldopa, labetalol, and hydral-
azine, for which oral diazoxide was later substituted. Nevertheless her
blood pressure continued to be unstable, repeatedly reaching 200/130
mm Hg but with a lower baseline of approximately 160/110mm Hg. The
peaks in arterial pressure were associated with prostrating paroxysms
of severe headaches, vomiting, and tachycardia. Plasma catecholamine
concentrations as well as urinary excretion of 4-hydroxy 3-methoxy
mandelic acid (HMMA) were normal. She continued to have protein-
uria (up to 2.3 g/24 hours), but renal function remained normal; plasma
creatinine was always less than 0.7 mg/dl and uric acid less than 5.0
mg/dl. Repeated midstream samples of urine were unremarkable except
for asymptomatic bacilluna that was treated appropriately. The platelet
count was always greater than 250,000/mm3, but the Factor VIII ratio
rose slowly to 2.27 by the 35th week of pregnancy.
At 35 weeks, labor was induced. The patient delivered vaginally a
healthy son weighing 2340 g (lOth—25th percentile) who did not need
special care. After delivery the patient's symptoms and the instability of
her blood pressure remitted. On discharge, propranolol, 160 mg four
times a day, was prescribed. Six weeks later the blood pressure was
148/98 mm Hg, renal function was normal, and no proteinuria was
present. She was feeling extremely well.
She remained under the care of her local physician until 3 years later,
when she presented at 16 weeks into her second pregnancy. She was
taking atenolol and the blood pressure was 160/100 mm Hg. The course
of the second pregnancy was characterized, as was the first, by
paroxysms of prostrating headaches, vomiting, extreme hypertension,
and tachycardia. A CT scan of the skull was normal. By the end of her
pregnancy she was taking atenolol, methyldopa, slow-release
nifedipine, and an antiemetic. Her renal function remained normal.
Proteinuria was recorded sporadically but never reached more than 0.4
g/24 hours. After a normal delivery at 35 weeks (a healthy daughter,
2160 g, loth—25th percentile for gestational age), her symptoms again
remitted; by 6 weeks postpartum the blood pressure was 158/84 mm Hg
while she was taking atenolol, and she felt entirely well. Renal function
was normal and proteinuria had disappeared.
Discussion
DR. CHRISTOPHER W. G. REDMAN (University Lecturer and
Consultant in Obstetric Medicine, University of Oxford, Ox-
ford, U.K.): In her first pregnancy the patient was transferred at
23 weeks gestation with the provisional diagnosis of severe
pre-eclampsia superimposed on pre-existing hypertension. It is
unusual but not rare for cases of pre-eclampsia to present
between 20 and 28 weeks; indeed rare cases have been reported
to occur even before 20 weeks of pregnancy [1]. Presentation
before 28 weeks creates a particular problem because delivery
under these circumstances may be incompatible with fetal
survival.
Pre-eclampsia usually progresses through three distinct
stages: hypertension alone, proteinuric hypertension without
symptoms, and proteinuric hypertension with symptoms.
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Finally, eclampsia ensues. Characteristically, the speed of the
progression accelerates so that the symptomatic third stage may
last only a few hours and, at most, a few days. A woman with
symptomatic pre-eclampsia therefore must be delivered without
delay regardless of gestational maturity. At presentation this
patient appeared to have proteinuric pre-eclampsia without
symptoms (stage 2), which shortly afterwards was associated
with severe headaches and vomiting—the typical pre-eclamptic
symptoms. Thus an argument could have been made for urgent
delivery. But several of her features were so atypical that we
believed the diagnosis of pre-eclampsia could be excluded with
reasonable certainty and that the pregnancy could be continued
safely. Today I will discuss this patient in some detail, simul-
taneously examining some of the major characteristics of the
pre-eclamptic syndrome.
The pre-eclamptic syndrome: Primary pathology
Because pre-eclampsia has no known cause, there is no
precise diagnostic test—the condition can be identified only as
a syndrome. The primary pathology, which is within the uterus,
results from the presence of trophoblast but not necessarily a
fetus because pre-eclampsia can occur with hydatidiform mole
[2]. The fundamental problem is probably an insufficient blood
supply to the placenta. In the first half of pregnancy, the spiral
arteries of the placental bed are infiltrated by trophoblast; this
process causes these arteries to dilate [3]. Then the uteropla-
cental blood flow can increase normally in the second half of
pregnancy. In pre-eclampsia this process fails [4]. The ensuing
restriction in uteroplacental perfusion is exacerbated by the
development of obstructive lesions of the spiral arteries; these
lesions, termed "acute atherosis," are composed of lipid-filled
macrophages and thrombi [5], Uteroplacental blood flow is
reduced [6], and the placenta shows histologic features of
ischemia [7] or frank infarction [8]. Placental ischemia is thus a
major feature of pre-eclampsia.
The maternal features of pre-eclampsia are thought to be
secondary to the underlying placental ischemia, although defi-
nite proof is still lacking. However, there is circumstantial
evidence in that several animal models of pre-eclampsia have
been produced by inducing placental ischemia [9—Il]. The
maternal manifestations of pre-eclampsia can involve the arte-
rial tree, the clotting system, the kidney, the liver, and the
nervous system, but the specific pattern of maternal abnormal-
ities varies greatly from one individual to another.
Secondary involvement of the arterial tree
Systemic hypertension in pre-eclampsia primarily results
from an increase in peripheral resistance [12]; cardiac output
typically remains unchanged [13]. The hypertension is preceded
by increased reactivity of the maternal circulation to the infu-
sion of angiotensin 111141; this finding is thought to be mediated
by changes in prostanoid metabolism [15]. Typically, a pre-
eclamptic woman has an unstable arterial pressure despite bed
rest [16] with a loss, and ultimately a reversal [17], of the
normal, nocturnal fall of the pressure during sleep.
The differential diagnosis of hypertension
in pregnancy
Hypertension in the second half of pregnancy is a common
and difficult problem. Frequently recordings of the woman's
arterial pressure before she became pregnant are not available.
Pregnancy normally induces a fall in pressure that occurs
mainly during the second half of the first trimester [18] and in
some cases is large enough to obscure pre-existing hyperten-
sion. An extreme example has been reported of a woman whose
pre-pregnancy blood pressure readings were 224—280/140—180
mm Hg; during pregnancy the pressure fell without treatment
(not available at the time) to 110—130/60—80 mm Hg [19]. The
blood pressure normally rises to pre-pregnant levels at the end
of the third trimester; women whose pressure falls in mid-
trimester are those whose pressure rises at the end of pregnancy
[20]. Hence a rise in the arterial pressure in the third trimester
from earlier, normal levels does not necessarily indicate pre-
eclampsia. The significance of the change can be assessed only
retrospectively by later, postpartum investigation.
Diagnosing pre-eclampsia is easier when a well-documented
series of blood pressure readings before pregnancy is available.
If the pregnancy progresses normally, the blood pressure may
run at a higher baseline in chronically hypertensive women, but
other features of pre-eclamptic hypertension are not present,
including baseline blood pressure instability, altered circadian
rhythm, and increased pressor sensitivity to exogenous angio-
tensin II [21].
Hypertension with paroxysmal features, as exemplified by
the present patient, suggests pheochromocytoma. The presen-
tation of pheochromocytoma in pregnancy can simulate pre-
eclampsia, with similar symptoms, unstable hypertension, and
proteinuria. The symptoms can remit between pregnancies [22].
Maternal mortality from pheochromocytoma is high [23], par-
ticularly postpartum. For this reason, all women with severe
pre-eclampsia, regardless of symptoms, should be screened for
the presence of pheochromocytoma. The usual tests of urinary
catecholamines or their metabolites can yield false-negative
results; a maternal death from pheochromocytoma was re-
corded with three normal results for urinary VMA excretion
[24]. If one suspects pheochromocytoma, plasma catechol-
amine levels should be measured. In the patient we are discuss-
ing today, the possibility of a pheochromocytoma already had
been investigated before pregnancy, and two attempts using CT
scans to localize a tumor had been negative. Additional mea-
surements of plasma and urinary catecholamines were normal
during the pregnancy.
Unstable blood pressures and severe headaches occur during
the third trimester and in labor in women with high spinal cord
transections (autonomic hyperreflexia) [25]. The paroxysms
frequently are triggered by distension of the hollow viscera [26]
and depend on intact autonomic spinal reflexes released from
hypothalamic control. The problem may be induced for the first
time or exacerbated in paraplegic women during pregnancy and
then resolve after delivery [27]. Today's patient did not have a
spinal lesion but had sustained a head injury and hemiparesis. It
is possible, but not likely, that higher control of spinal reflexes
had become disturbed at the same time, leading to the vasomo-
tor instability that was a central feature of her pregnant state.
Other causes of hypertension are unlikely to explain the
paroxysms experienced by this woman. There was no evidence
of active glomerulonephritis, and a major degree of interstitial
nephritis had been excluded by the normal pyelogram and renal
function. Renal arteriograms had not been obtained (at the
patient's request) and so renovascular hypertension could not
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Fig. 1. Serial measurements of maternal plasma urate (•-_-), blood
platelet count (O---O), and 24-hr urinary albumin excretion (A-—A)
from a patient who developed proteinuric pre-eclampsia requiring
elective delivery at 32 weeks of pregnancy. PN1 and PN2 refer to
measurements I and 6 weeks after delivery. Urinary albumin was
measured by a double antibody radioimmunoassay with a sensitivity of
125 pg/liter. The change in urinary albumin excretion was sudden and
was preceded by a rising plasma urate and falling platelet count. 0.2 and
0.4 mM of urate are equivalent to 3.4 and 6.8 mg/dl respectively.
(Reproduced from Ref. 30.)
be discounted. The histories of the few published cases of renal
artery stenosis in pregnancy have been unlike that of the patient
under discussion and, in particular, without mention of parox-
ysmal hypertension or symptoms.
Secondary involvement of the renal system
Renal involvement in pre-eclampsia, one of the syndrome's
more consistent features, has long been recognized. The pres-
ence of proteinuria reflects advanced disease and is associated
with a poorer prognosis [28]. If persistent proteinuria in excess
of 0.5 glday is present, our experience indicates that conserv-
ative management can prolong the pregnancy by 12 days on
average (unpublished data). The relentless progression of pre-
eclampsia then produces problems that make delivery inevita-
ble. These problems include uncontrollable hypertension, dete-
riorating renal function, clotting or hepatic abnormalities, nau-
sea, vomiting, headaches (phase 3 of the disease), or impending
fetal death. There is considerable variability in the time course:
in some, the proteinuric phase lasts 2 or 3 days only; in others,
it may extend to 3 weeks or more. Hence, in clinical practice,
the concept of proteinuric pre-eclampsia is useful. After about
34 weeks of pregnancy, proteinuria identifies a situation that is
best resolved by elective delivery without delay. At earlier
stages of pregnancy, delivery can be delayed despite the
presence of proteinuria; the expected gain in fetal maturity is
small but not necessarily trivial.
Cases of eclampsia, without proteinuria, have been reported
[291, hence neurologic complications can be severe in the
absence of severe renal involvement. This paradox illustrates a
general principle of diagnosis of syndromes such as pre-
Molecular
weight
(daltons)
Protein clearance (% of
transferrin clearance)
Transferrin 90,000 IlOO%J
Albumin 69,000 99.4 11.7
IgG 160,000 23.7 3.7
B1A/C globulin 250,000 4.6 2.0
Pseudocholinesterase 300,000 4.8 2.2
Alpha-2-macroglobulin 820,000 1.0 0.3
1gM 1,000,000 0.8 0.3
eclampsia: the absence of a single sign never excludes with
certainty the problem in question.
The proteinuria in pre-eclampsia is not preceded by a phase
of microalbuminuria [301 (Fig. 1). The proteinuria is moderately
selective [311 (Table I), increases until the time of delivery, and
occasionally exceeds 10 g124 hours. Indeed, pre-eclampsia is
the commonest cause of heavy proteinuria in pregnancy [321. A
nephrotic syndrome can ensue in which generalized edema,
hypoproteinemia [33], reduced plasma oncotic pressure [341,
and hypovolemia [35] can be present. Serous effusions, partic-
ularly ascites, occur. Respiratory difficulties may arise from
laryngeal edema [361 or pulmonary edema [371; cerebral edtma
can occur [381 and is a possible cause of at least some cases of
eclampsia.
Renal involvement in pre-eclampsia has other well-doc-
umented features, including characteristic glomerular histology
and changes in function. We do not use renal biopsy in the
differential diagnosis of pre-eclampsia, however atypical or
difficult the presentation. Biopsy is reserved for patients with
persistent, significant proteinuria and renal impairment long
after delivery. It has been claimed [39] and denied [40] that the
glomerular lesions are pathognomonic. The former view incor-
porates a logical paradox because it implies that pre-eclampsia
is a primary renal disease, which is improbable, given that
pre-eclampsia is not merely pregnancy specific but, in most
cases, parity specific. Normal renal histology has been docu-
mented in some patients with eclampsia [41], so this finding
does not exclude the diagnosis. The variable degree to which
the kidneys are involved (measured by proteinuria, changes in
function, or renal histology) is to be expected if these are
secondary manifestations of a primary uteroplacental problem.
The glomerular endothelial cells are found to be swollen, a
histologic abnormality that has been termed "glomerular
endotheliosis" [391. Opinions differ as to whether the endothe-
hal and mesangial cells proliferate [42—44] or the basement
membrane is affected [44, 45]. Subendothelial electron-dense
deposits typically are found [421, but the epithelial foot pro-
cesses remain intact. Similar changes are found in the renal
biopsies of women who have suffered placental separation—
which may be complicated by shock and disseminated intravas-
cular coagulation (DIC) [46]. This observation has two possible
interpretations. Either the lesion is not specific for pre-
eclampsia (but to antenatal DIC), or the placental abruption
Delivery Table 1. Protein clearance in 16 patients with preeclampsiaa
p
The 16 patients were selected because of a rise in arterial pressure
to 140/90mm Hg or more with the onset of proteinuria (0.8—9.6 g/24 hr).
The slope of the regression line of urinary clearance against molecular
weight was used as an index of selectivity which, for these patients, was
intermediate in value. (Adapted from Ref. 31.)
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Serum urea
nitrogen
(mg/dl)
Serum uric
acid (mg/dl)
Normal women (third trimester) 8.95 2.36
(30)
3.57 0.69
(30)
Chronic hypertension 10,75 4.32
(10)
3.71 1.07
(12)
Pre-eclampsia, severity 1+ 9.22 2.50
(9)
5.53 1.74
(12)
Pre-eclampsia, severity 2+ 10.82 3.37
(11)
6.33 1.37
(12)
Pre-eclampsia, severity 3+ 13.06 4.72
(9)
7.76 1.54
(9)
a The diagnoses in this study were made by renal biopsy carried out
during pregnancy. The grading of the severity of pre-eclampsia is
histologic. The serum measures are given as mean one standard
deviation, with the numbers of observations in parentheses. From these
data it was concluded that the best clinical correlate of the glomerular
pathology was provided by serum uric acid measurements. (Adapted
from Ref. 45.)
Mean age (years) 26.6 4.3
Primipara 9/14
Gestational age (weeks S.D.) at:
First assessment 17.3 2.8
Time of rising plasma uric acid 25.2 3.8
Time of rising plasma urea 28.3 3.1
Onset of proteinuria (11 patients only) 28.6 3.1
Delivery 31.8 2.8
Mean birthweight (kg) 1.3 0.4
Surviving infants 10/14
a The 14 patients were studied serially through pregnancy, from an
average gestational age of 17 weeks until early delivery. Rising plasma
uric acid and urea levels were considered present if measurements were
consistently 2.0 mg/dl and 5.0 mg/dl, respectively, above baseline
levels. The onset of hyperuricemia before proteinuria is demonstrated.
(Adapted from Ref. 51.)
complicates unrecognized pre-eclampsia. In rabbits, lesions
that resemble glomerular endotheliosis can be induced by DIC
stimulated by infusing thromboplastins [47]; this finding lends
support to the former interpretation. Furthermore, some claim
that fibrin deposition in the glomeruli is a consistent feature
[481, which could be the cause, rather than the consequence of,
glomerular injury. But the glomerular fibrin is not found in all
cases [42, 44]. Alternatively some consider that glomerular
injury could be mediated by immune complexes. Immunofluo-
rescence studies show deposition of 1gM in the glomeruli [42,
49] but this feature also is not consistent [42, 44]. Further
uncertainties arise because the time course of the renal biopsy
changes cannot be studied in detail, and the time course of
pre-eclampsia itself is poorly understood, as is its relation to
placental abruption. It would be almost impossible to prove or
disprove that latent pre-eclampsia preceded all cases of placen-
tal separation. This hypothesis is, however, intrinsically un-
likely, because abruption is, in general, a disorder of parous
women, whereas pre-eclampsia affects primiparas. Thus I con-
clude that renal biopsy does not provide a completely specific
or sensitive diagnosis for pre-eclampsia. The heterogeneity of
renal pathology and responses probably reflects the range of
different maternal adaptations to placental ischemia.
Thus the clinical severity of pre-eclampsia may appear not to
correlate with the degree of glomerular pathology [50]. How-
ever, in the most comprehensive study, there was a close
association between the severity of the renal lesions and two
other indices of the disease—retinal arteriolar spasm and
hyperuricemia [451. The relationship with hyperuricemia has
been confirmed [43] and denied [41].
Hyperuricemia, a well-documented finding in pre-eclampsia,
is usually an early feature [51] (Tables 2 and 3). It precedes the
onset of proteinuria and hence is useful for diagnosis during the
first, non-proteinuric stage. Pregnant women with chronic hy-
pertension alone have normal plasma urate concentrations. So,
a patient with both hyperuricemia and hypertension in the
second half of pregnancy is more likely to have pre-eclampsia
than underlying chronic hypertension, even in the absence of
proteinuria, and hence to have a worse perinatal outcome [52].
Plasma urate normally rises in the third trimester (Fig. 2); as a
rough guide, values above 5.0, 6.0, 7.0, and 7.5 mg/dl at 28, 32,
36, and 40 weeks, respectively, if associated with hypertension,
are likely to reflect pre-eclampsia. But just as pre-existing
hypertension can muddle the presentation of pre-eclamptic
hypertension, so can pre-existing hyperuricemia. In addition,
transient hyperuricemia during pregnancy can, as in any situa-
tion, have other causes (for example, administration of diuret-
ics, metabolic acidosis) [53, 54]. Like most other signs of
pre-eclampsia, hyperuricemia is a variable feature of the con-
dition and sometimes may not be present even in patients with
eclampsia [41].
Whether or not the pre-eclampsia is superimposed on chronic
hypertension, hyperuricemia results from a reduced renal clear-
ance of urate [55, 56]. The renal clearance of urate is reduced
out of proportion to the reduced clearance of inulin [55].
Hyperuricemia can be exacerbated by eclamptic fits [57] prob-
ably because of complicating hypoxia and lactic acidosis. The
Table 2. Renal function in preeclampsiaa 300
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I
F00
16
Maturity of pregnancy, weeks
Fig. 2. Serial changes in plasma uric acid from 16 weeks of pregnancy
to 6 weeks after delivery (PN) were measured in a single cohort of
normal primigravidae. Plotted are the changes from the baseline
reading at 16 weeks maturity. The three lines are the 10th, 50th, and
90th centiles. 100 M of uric acid is equivalent to 1.69 mg/dl.
Table 3. Evolution of severe pre-eclampsia in 14 patients
followed seriallya
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Fig. 3. Serial changes in the ratio of plasma Factor Vill-related antigen
to Factor VIII procoagulant activity were measured in a single cohort
of normal primigravidae. The expected value for non-pregnant individ-
uals is 1.0. In normal pregnancy a slightly higher ratio is present until 32
weeks, increasing further until full term. The three lines are the 10th,
50th, and 90th centiles. Thus ratios above 2.0 at 32 weeks, 2.25 at 36
weeks, and 2.5 at 40 weeks are unusual and more typical of pre-
eclampsia.
mechanisms responsible for these alterations in renal function
are not defined.
In the present patient, proteinuria was associated with exac-
erbation of pre-existing hypertension. Initially the patient ap-
peared to have superimposed pre-eclampsia at 23 weeks of
pregnancy. If correct, the pregnancy needed to be terminated,
especially because the patient had symptoms that also are
encountered just prior to seizures. However, retinal arteriolar
spasm and hyperuricemia both were absent. These findings
supported the tentative conclusion that the underlying condi-
tion was not severe pre-eclampsia.
Secondary involvement of the clotting system
The maternal clotting system is another target for the pre-
eclamptic process. In the terminally ill patient with pre-
eclampsia or eclampsia, there is disseminated intravascular
coagulation with gross abnormalities in hemostasis and in
simple clotting tests, reflecting consumption of clotting factors
and platelets. Plasma fibrin/fibrinogen degradation products are
increased. The problem was first defined by autopsy studies
[581, although the associated microangiopathic hemolysis had
been recognized, but not explained, earlier [59].
The hypothesis that the maternal signs of pre-eclampsia are
mediated by activation of the clotting system has not. been
substantiated. The absence of gross clotting disturbances in the
majority of eclamptic women [601, or in pre-eclamptic women
[61], is evidence against a primary role and demonstrates that
the convulsions are not caused by DIC. However, the early
stages of pre-eclampsia may be characterized by alterations in
the clotting system that fall short of DIC but deviate far enough
to be recognized as abnormal. The easiest to detect is
thrombocytopenia [62]. Another index that frequently becomes
abnormal at an early stage is the relative plasma concentrations
of Factor VIlI-related antigen (RA) and Factor VIII clotting
activity (CA) expressed either as a ratio [63] or as a difference
[64]. Both measurements are increased in normal pregnancy
relative to the non-pregnant state (Fig. 3) and increase further
when pre-eclampsia develops [63, 64]. These changes occur
because either Factor VIII activity is destroyed by generation
of intravascular thrombin or because more Factor VIlI-related
antigen is released into the circulation, possibly by damaged
endothelium. In the patient under discussion, the platelet count
and Factor VIII RA/CA ratio were normal at presentation. Both
measurements remained normal until delivery, although the
Factor VIII RA/CA ratio had reached the upper limit of normal
for gestational age.
The cause of the disordered clotting system in pre-eclampsia
is not known. Various theories include direct activation by
products from a damaged placenta [65], or activation secondary
to hypertensive arterial damage [60] or immunologic mecha-
nisms [661. Recently a more central role for platelets has been
proposed. The balance between the opposing actions of throm-
boxane and prostacyclin may be tipped towards the proag-
gregating and vasoconstrictor effects of thromboxane A2 pro-
duced by platelets. There is also evidence for the production of
too little prostacyclin by vascular endothelium [67] and too
much thromboxane by the placental unit [68]. The effects of
antiplatelet agents have been tested using aspirin [69],
dazoxiben [70], or intravenous prostacyclin [71]. Two con-
trolled trials employing low-dose aspirin [72] or low-dose aspi-
rin with dipyridamole [73] have shown an improved outcome
with treatment. These studies lend credence to the concept that
platelets play a key role in the genesis of pre-eclampsia [741.
Severe thrombocytopenia in pre-eclampsia or eclampsia can
be life-threatening [75], and this presentation has been confused
with thrombotic thrombocytopenic purpura [76]. The combina-
tion of pre-eclamptic liver damage and thrombocytopenia pro-
duces a syndrome known by the acronym "HELLP"—hemo-
lysis with elevated liver enzymes and low platelet counts [77].
Plasma aspartate aminotransferase (AST) activity should be
measured in all patients suspected of having pre-eclampsia.
Liver involvement occurs frequently, even in patients without
severe hypertension or renal involvement [78]. In the present
patient, liver damage was not evident at any time; this finding is
consistent with the persistently normal platelet counts.
Secondary involvement of the fetus
The diagnosis of pre-eclampsia must include a detailed con-
sideration of the fetus. Thirty years ago such a consideration
extended only as far as detecting the fetal heartbeat. Now it is
possible to measure fetal size accurately, estimate fetal respi-
ratory status by heart-rate analysis, and assess uteroplacental
and fetoplacental arterial flow patterns by ultrasound Doppler
techniques. The uteroplacental arterial disease of pre-eclampsia
and the ensuing placental dysfunction ensure that the fetus will
be "compromised," particularly when the patient presents with
proteinuria (stage 2) before 32 weeks of pregnancy [79]. The
term "compromised" as applied to the early stages of pre-
eclampsia means smaller than expected for gestational age, but
it also applies to the progressive development of hypoxemia,
acidosis, and asphyxiation of the fetus. Intrauterine death is a
likely outcome if the fetus is not delivered in time. If delivery is
delayed in unequivocal, early-onset proteinuric pre-eclampsia,
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the most common outcome (after an average of 12 days, as
already indicated) is progressive fetal compromise. One is then
forced to choose between delivery far before term or inevitable
fetal death.
In today's patient, the results of fetal assessment were
normal and remained so for more than 3 months from the time
of first presentation. The ultrasound measurements indicated
normal fetal growth. Fetal heart-rate analysis suggested that
fetal respiratory status was normal. Reassured, we considered
these findings the best evidence for a diagnosis other than
severe pre-eclampsia and justification for our decision to allow
normal labor instead of performing an elective cesarean section.
Ultrasound measurements were borne out at delivery by the
finding that the birth weight was normal. The placental circu-
lation had enough reserve to maintain fetal health through labor
so that, at delivery, not only were the Apgar scores good, but
the umbilical venous and arterial blood pH and gases were
normal. These findings were the final, albeit indirect, proof that
the spiral arteries were healthy, sustaining a normal uteropla-
cental circulation and fetus, and not affected by pre-eclampsia.
Summary: Principles of the diagnosis
of pre-eclamnpsia
My central hypothesis in this discussion is that pre-eclampsia
is not primarily a hypertensive or renal disorder, but a disease
of pregnancy, probably of the uteroplacental arterial system. In
support of this hypothesis are the following:
(1) Because the healthy placenta ultimately is responsible for
the wide array of normal maternal physiologic adjustments to
pregnancy, the ischemic placenta might be expected to cause a
diverse set of systemic disturbances such as that seen in
pre-eclampsia;
(2) None of the signs of pre-eclampsia, as currently defined,
are specific for the disorder;
(3) The fetus is affected as well as the mother;
(4) The disorder cannot be understood solely in terms of the
involvement of one maternal system (arterial or renal or other).
The maternal signs of pre-eclampsia comprise a diverse and
highly variable set of nonspecific changes involving different
organ systems; these alterations defy simple stereotyping.
Without a specific test, a precise diagnosis cannot be made
prospectively, nor are there any absolute criteria by which the
diagnosis can be validated retrospectively.
The patient under discussion illustrates that some maternal
problems can masquerade as pre-eclampsia. Despite the sever-
ity of her hypertension and the presence of proteinuria, I
concluded that this patient did not have pre-eclampsia, and
hence was willing to counsel continuation of the pregnancy
rather than termination before fetal viability had been reached.
I was persuaded to pursue this unconventional course because,
in the aggregate, she did not manifest many of the more
common features of the pre-eclamptic syndrome. She was not
hyperuricemic, had no abnormalities of liver function, main-
tained a normal platelet count, and had no abnormalities of the
clotting system; in addition, there were no signs of fetal growth
retardation or fetal distress. Although her signs and symptoms
regressed after delivery, as would also have been the case had
she had pre-eclampsia, the course of the patient's next preg-
nancy corroborated the view that, rather than pre-eclampsia,
she had had an abnormal maternal response to an otherwise
normal pregnancy. Except for proteinuria, all the features that
characterized the first pregnancy recurred, and again they
regressed after delivery. Pre-eclampsia is predominantly a
disorder of first pregnancy [801, to such an extent in fact that the
proportion of nulliparae in published series has been used to
"test" the validity of methods of diagnosis [50].
Finally, patients such as the one we are discussing provide
evidence that the uteroplacental arteries are not unusually
sensitive to maternal hypertension, and strengthen the conclu-
sion that hypertension itself is not a mediating factor in the
evolution of pre-eclampsia [811.
Questions and answers
DR. PAUL SACKS (Renal Fellow, University of Chicago,
Chicago, Illinois): What are the mechanisms of the decreased
uric acid clearance by the kidney in patients with pre-eclamp-
sia?
DR. REDMAN: There is reduced fractional urate clearance,
but the precise mechanism underlying this change is not known.
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pital, Chicago): The relative degree of intravascular hypovole-
mia in pre-eclampsia in comparison to normal pregnancy might
be a plausible explanation for a decrement in the fractional
clearance of urate. In addition, some claim that catecholamine
excretion increases in pre-eclampsia, and that this rise causes a
decrease in urate clearance.
DR. REDMAN: I am not convinced that either hypovolemia or
catecholamine excess are adequate explanations. The degree of
expansion of the plasma volume in normal pregnancy is corre-
lated with the size of the fetoplacental unit; hence greater
changes are seen with twin pregnancies, which in turn are
exceeded by those occurring with triplet or quadruplet pregnan-
cies. Conversely, pregnancies with intrauterine growth retarda-
tion are associated with a relatively contracted plasma volume
whether or not pre-eclampsia is also a feature. In other words,
the changes in plasma volume in pre-eclampsia may be more a
consequence of fetoplacental size than of pre-eclampsia itself.
Not all pre-eclamptic pregnancies are complicated by fetal
growth retardation, especially when pre-eclampsia progresses
rapidly. In these cases, plasma volume has not been assessed,
but I would be surprised if such patients are hypovolemic,
although I would expect to find hyperuricemia. The problem
about invoking increased plasma catecholamines as an expla-
nation is that some studies report increased levels, some
decreased levels, and some report no changes. With this
confusion I find it difficult to believe that these hormones are
significant pathogenetic factors.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital, Chicago): The reduction in urate
clearance seems disproportionate to other manifestations of
renal dysfunction. Doesn't this observation suggest that some-
thing more specific is causing the defect in tubular function in
pre-eclampsia? For example, might some factor released from
the placenta be interfering specifically with urate transport?
DR. REDMAN: Yes, it could. But tubular function in pre-
eclampsia has never been evaluated extensively. The old theory
that placental acidosis generates lactate that would compete
with urate in the excretory pathways has, however, now been
disproved.
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DR. COHEN: You offered some circumstantial evidence that
uteroplacental arterial disease is primary in pre-eclampsia; that
is, histologic changes in the placenta that occur during pre-
eclampsia sometimes are seen in pregnancies unassociated with
hypertension. This finding suggests that these histologic
changes are not secondary to hypertension. Do we know what
the placental blood flow is under circumstances in which
characteristic histologic changes are present, but in which
pre-eclampsia is not? It seems to me that your thesis would
require that placental blood flow be compromised in patients
with pre-eclampsia but not in those with similar histologic
changes but without hypertension.
DR. REDMAN: It is impossible to measure uteroplacental
blood flow directly. Various clearance studies using radioiso-
tope tracers have been done in the past, but they cannot be
repeated because of concerns that the fetus will receive excess
amounts of radiation. Arterial flow velocity patterns can be
measured using ultrasound Doppler techniques. They reflect
various attributes of the circulation up- and downstream of the
arterial segment studied; unfortunately, flow itself cannot be
deduced. The measurements about which you ask therefore
have not been made. When spiral artery pathology is present
without a pre-eclamptic syndrome, there is always fetal growth
retardation. This observation suggests that uteroplacental flow
is reduced regardless of whether maternal hypertension is
present.
DR. BRIAN DUFFY (Attending Nephrologist, Michael Reese
Hospital): When nephrotic patients become pregnant, one of
the important signs of pre-eclampsia—the onset of protein-
uria—is obscured. Could one use the selectivity of the protein-
uria in these patients as a guide?
DR. REDMAN: I know of no study that provides a baseline for
such an approach to clinical management. However, I believe
that even in the patient with nephrotic syndrome the principles
of diagnosing pre-eclampsia are still the same except that an
increment in proteinuria is sought, in association with the other
possible signs of superimposed pre-eclampsia. Quantifying pro-
tein excretion generally is simpler than measuring selectivity of
proteinuria.
DR. SUSAN Hou (Renal Section, Michael Reese Hospital):
Would you comment on your use of nifedipine in this patient
and in other pre-eclamptic patients?
DR. REDMAN: We have used nifedipine for the treatment of
pre-eclamptic hypertension as a second-line drug to methyldo-
pa. In our limited experience it appears to be safe, but we do not
regard its safety for the fetus as entirely proven. It certainly has
advantages over both hydralazine and diazoxide. We do not use
magnesium sulfate to treat our patients, and any possible
interaction between this agent and nifedipine has not been
examined.
DR. COHEN: Does aggressive treatment of the hypertension
alter the natural history of pre-eclampsia?
DR. REDMAN: No, except insofar as it can help prevent
cerebral hemorrhage. In this respect medical treatment is an
adjunct to the definitive management, which is always delivery.
All the evidence suggests that the disorder begins and develops
independently of the blood pressure, which is a secondary sign
of some other, more fundamental, process.
DR. ARNOLD BERNS (Attending Nephrologist, Michael Reese
Hospital): Would you comment in more detail on the recent
data suggesting that low-dose aspirin is useful for prophylaxis of
pregnancy-induced hypertension and pre-eclampsia?
DR. REDMAN: This treatment is based on investigations
which show that the disorder is associated with a deficiency of
prostacylin release from the arterial wall and an excess produc-
tion of thromboxane. There have been two trials. In the first,
Beaufils used aspirin combined with dipyridamole in a hetero-
geneous group of high-risk, mainly parous women [73]. He
showed a modest benefit after starting treatment early in the
second trimester. The second trial was more precise in that the
subjects, all of whom were primigravidas, were selected on the
basis of an angiotensin infusion test. Only those who showed an
excess response were selected for randomization either to
low-dose aspirin (without dipyridamole) or placebo [721. Again
the aspirin therapy, started at 28 weeks of pregnancy, was
associated with benefit in terms of the eventual outcome. We
need further, much larger trials, to test low dose-aspirin under
conditions that more closely correspond to ordinary clinical
practice. If these studies showed the same sort of benefit, then
for the first time we would have a medication that would change
the outcome of this condition.
DR. FREDRIC COE (Renal Section, Mitchell Hospital): Do I
understand correctly that you regard pre-eclampsia as a syn-
drome in which the spiral arteries must always be involved and
that that is the basis for classifying a patient as having pre-
eclampsia? Or is the basis that some complex of findings must
reach a critical threshold? This woman clearly was excluded
from the diagnosis, perhaps because her baby did well. Could
you clarify the current definitive basis for calling someone a
victim of pre-eclampsia?
DR. REDMAN: Yes; I regard pre-eclanipsia as a disorder of
the placenta, a consequence of poor placentation. Poor placen-
tation, amongst other changes, prevents the spiral arteries from
dilating and thus providing the uteroplacental blood flow nec-
essary for the second half of pregnancy. The major physiologic
changes of pregnancy are due to the presence of a healthy
placenta in the uterus. Pre-eclampsia, I believe, represents the
aggregate of changes caused by the presence of a sick (isch-
emic) placenta. I find this a useful model, one that explains all
that I see in my clinical practice. I do acknowledge that proof of
its correctness is lacking.
Developing a precise definition of pre-eclampsia at present
may have the merit of achieving linguistic uniformity, but it
blocks further evolution of thought about one (or several)
poorly understood disorders of pregnancy. We are in the
common situation where arguments arise because of a lack of
knowledge. In this presentation, I have put forward a working
hypothesis that was helpful in the management of this patient.
To me this hypothesis has been tested under difficult circum-
stances and found to be adequate. Clearly more definitive
information is urgently needed.
DR. C0E: To reiterate, what we must look for in clinical
practice, if we are to consider the diagnosis of pre-eclampsia, is
a hypertensive syndrome in association with evidence that the
fetus is doing poorly. I am trying to clarify, at least from a
clinical point of view, when we would dare take the chances
that you took with the patient under discussion.
DR. REDMAN: No, this is not what I mean. Pre-eclampsia
has, if you like, two components—maternal and fetal—occur-
ring together in highly variable combinations of severity. The
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letal component, that is, smallness with or without evidence of
respiratory insufficiency, is usually but not invariably present.
In some cases, the maternal component apparently is dispro-
portionately severe relative to the fetal. The converse also can
happen; that situation is more familiar to obstetricians than to
internists. In the patient we have discussed today, the maternal
component was not convincingly pre-eclampsia, because nei-
ther hyperuricemia nor involvement of the clotting system was
present. The absence of a fetal component provided strong, but
not perfect, supporting evidence that the patient did not have
pre-eclampsia. But in terms of clinical practice it is not possible
to "exclude" pre-eclampsia simply because the fetus appears to
be uninvolved. If the fetus does appear to be normal, however,
the other conditions that can masquerade as pre-eclampsia must
be considered seriously.
DR. ALAN SEGAL (Medical Resident, Michael Reese Hospi-
tal): You have theorized that pre-eclampsia is a disease of the
uteroplacental junction, specifically of the spiral arteries, and
you have noted that some patients have normal renal biopsies,
which I presume includes the absence of fused podocytes on
electron microscopy. Given this observation, what is the cause
of the proteinuria in pre-eclampsia?
DR. REDMAN: In pre-eclampsia the foot processes of the
renal glomeruli are intact. So the mechanism of the proteinuria
relates to a different process that has yet to be defined. As I
mentioned, if a pregnant woman has an acute abruption, and
her clotting system is activated, she will develop changes in her
renal biopsy and proteinuria. One theory is, therefore, that the
proteinuria is the consequence of fibrin deposition in the
glomeruli,
DR. LINDHEIMER: The failure of trophoblasts to invade the
spiral arteries, which thus don't "dilate," as well as the uterine
ischemia theory of pre-eclampsia ought to be very appealing to
nephrologists. In essence we convert the "Goldblatt kidney"
model of hypertension to a "Goldblatt uterus." Unfortunately,
not all the data in the literature support this view. Of greatest
interest is the series of observations from the group at Parkland
Hospital in Dallas. These data suggest that placental blood flow
is actually increased early in the course of gestation in individ-
uals who subsequently develop pre-eclampsia, and only de-
creases when overt disease occurs. These observations were
based on the use of the placental clearance of dehydroisoan-
drosterone sulfate, androstenedione, etc. as "indices" of pla-
cental blood flow [82].
Another point that deserves focus in our discussion is the
concept of temporizing when a patient, such as the one dis-
cussed today, presents with severe hypertension at 23 weeks.
In your presentation you alluded to the fact that most authori-
ties agree that changes in the coagulation system or evidence of
hepatic dysfunction, such as elevated transaminase levels, are
danger signs of potential maternal disaster. Also, if we are
secure at 23 weeks that the patient has superimposed or pure
pre-eclampsia, fetal outcome is so poor even with temporiza-
tion that risks to the mother preclude continuation of the
pregnancy. In both instances, therefore, we would terminate
the gestation. Many of us also would worry about continuing
pregnancy in a mother when one cannot successfully control
her blood pressure. For instance, one may see the complica-
tions of hypertension in the fundi at lower mean blood pressures
during gestation compared with nongravid populations. There is
also a higher incidence of cerebral vascular accidents when
blood pressure is high during pregnancy. I think it is fair to say
that currently any mortality or any form of residual morbidity in
a young mother attributable to hypertension in pregnancy is
unacceptable. This is probably the reason for the aggressive
intervention tactics of fetal-maternal experts, sometimes to the
surprise of my fellow nephrologists and internists. Would you
comment on this?
DR. REDMAN: The studies you cite did not measure utero-
placental blood flow directly. Altered hormone clearances
might have reflected hypoxia-induced proliferation of tropho-
blast. I do not think, therefore, that the data from Texas are
difficult to accommodate within the hypothesis that I have
described.
With regard to the second part of your question, I agree that
any mortality or residual morbidity resulting from a system of
management of hypertension in pregnancy is unacceptable. It
cannot be emphasized too much that the patient presented
today is not an example of how to manage proteinuric pre-
eclampsia (that is, stage 2 or stage 3) at 23 weeks of gestation,
or indeed at any other time. If that had been the diagnosis, the
correct management would have been termination of the preg-
nancy, because we know that we can expect only 12 days of
extra time, on average, by temporizing. The decision not to
deliver was justified only in terms of our conviction that she did
not have pre-eclampsia. My purpose in presenting the case was
to show how this conclusion was reached, how it was tested,
and how it led to two successful pregnancies without ensuing
morbidity. The patient was extremely unusual, and it is improb-
able that we shall encounter another like her. Therefore, the
message concerns not so much the details of management, but
the conceptual approach to thinking about, and dealing with,
pre-eclampsia.
DR. COHEN: What is the long-term prognosis for women who
experience a pre-eclamptic pregnancy?
DR. REDMAN: A pre-eclamptic illness can provoke irrevers-
ible events such as renal cortical necrosis, cerebral hemorrhage
and infarction, or retinal detachment, which can lead to perma-
nent morbidity. The evidence from long-term followup studies
shows that, if these events do not happen, then those who were
pre-eclamptic as primigravidas enjoy a normal life expectancy.
Those who suffer pre-eclampsia in second or later pregnancies
have a higher incidence of cardiovascular disease in later life
and a reduced life expectancy.
DR. COHEN: Is the incidence of pre-eclampsia falling?
DR. REDMAN: The National Perinatal Surveys in 1958 and
1970 looked at unselected samples of deliveries in England and
Wales. Both studies used the same diagnostic criteria, and the
incidence of pre-eclampsia was similar in both surveys.
Reprint requests to Dr. C. W. G. Redman, John Radcllfe Hospital
Maternity Department, Headington, Oxford 0X3 9DU, England
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